- Home
- WALD vs AVIR Comparison
WALD vs AVIR Comparison
Compare WALD & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | WALD | AVIR |
|---|---|---|
| Founded | 1988 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 228.8M | 236.7M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | WALD | AVIR |
|---|---|---|
| Price | $1.85 | $3.16 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | $4.76 | ★ $6.00 |
| AVG Volume (30 Days) | 173.9K | ★ 348.1K |
| Earning Date | 11-24-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $274,560,000.00 | N/A |
| Revenue This Year | $4.61 | N/A |
| Revenue Next Year | $11.22 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 14.22 | N/A |
| 52 Week Low | $1.48 | $2.46 |
| 52 Week High | $4.18 | $4.02 |
Technical Indicators
Market Signals| Indicator | WALD | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 37.91 | 51.77 |
| Support Level | $2.18 | $2.99 |
| Resistance Level | $2.25 | $3.23 |
| Average True Range (ATR) | 0.25 | 0.09 |
| MACD | -0.09 | 0.02 |
| Stochastic Oscillator | 3.90 | 70.91 |
Price Performance
Historical ComparisonAbout WALD Waldencast plc
Waldencast PLC is a beauty and wellness operating platform. The company is organized into two reportable segments namely Obagi Skincare and Milk Makeup. The company generates the majority of its revenue from the Obagi Medical segment. The Obagi Medical segment is engaged in developing, marketing, and selling skin health products. The Milk Makeup segment includes developing, marketing, and selling cosmetics, skincare, and other beauty products. Geographically the company generates the majority of its revenue from North America region.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).